Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

University of Helsinki, GlaxoSmithKline (Belgium), Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Hospital de Clínicas de Porto Alegre, Mexican Social Security Institute, University of New Mexico, National Taiwan University Hospital, Sexual Health Clinic, Väestöliitto, University of Manchester, Hospital de Clínicas Universidade Federal do Paraná, The Kids Research Institute Australia, University of Western Australia, Dartmouth College, Ohio Pediatric Research Association, Chulalongkorn University, Makati Medical Center, Philippine General Hospital, Centre hospitalier universitaire de Québec, DDL Diagnostic Laboratory, Tampere University, Tampere University, GlaxoSmithKline (United States)